Skip to main content Skip to navigation

Beta interferon and glatiramer acetate

  • Association of British Neurologists (ABN).
    ABN Guidelines for the treatment of multiple sclerosis with beta interferons and glatiramer acetate.
    London: ABN; 2001.

  • Association of British Neurologists (ABN).
    Revised (2009) guidelines for prescribing in multiple sclerosis.
    London; ABN: November 2009.
    download (pdf 124kb)

  • Dubois BD, Keenan E, Porter B, et al.
    Interferon beta in multiple sclerosis: experience in a British specialist centre.
    J Neurol Neurosurg Psychiatry 2003;74(9):946-949.
    Abstract

  • Durelli L, Verdun E, Barbero P, et al.
    Every-other-day interferon beta1b versus once weekly interferon beta 1a for multiple sclerosis: results of a 2 year prospective randomised multicentre study.
    Lancet 2002;359(9316):1453-1460.
    Abstract

  • Frohman EM, Havrdova E, Lublin F, et al.
    Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at time of diagnosis.
    Arch Neurol 2006;63(4):614-619.

  • The IFNb Multiple Sclerosis Study Group.
    Interferon beta 1b in the treatment of multiple sclerosis: final outcome of randomised controlled trial.
    Neurology 1995;45:1277-1285.
    Abstract

  • Karussis D, Biermann LD, Bohlega S, et al.
    A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.
    Eur J Neurol 2006:13(1):61-71.
    Abstract

  • OWIMS study group.
    Evidence of interferon beta 1a dose response in relapsing remitting MS: The OWIMS study.
    Neurology 1999;53:679-86.
    Abstract

  • Panitch H, Goodkin DS, Francis G, et al.
    Randomised comparative study of interferon b1a treatment regimes in MS.
    The EVIDENCE trial - (Evidence for interferon dose effect: European-North American comparative efficacy).
    Neruology 2002;59:1496-1506.
    Abstract

  • Portaccio E, Zipoli V, Siracusa G, et al.
    Long term adherence to interferon beta therapy in relapsing remitting multiple sclerosis.
    Eur Neurol 2008;59(3-4):131-135.
    Abstract

  • PRISMS (Prevention of Relapses and Disability by Interferon beta- 1a Subcutaneously in Multiple Sclerosis) Study Group.
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis.
    Lancet 1998;352: 1498- 1504.
    Abstract

  • PRISMS Study Group.
    PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.
    Neurology 2001;56:1628-1636.
    Abstract

  • Rudick RA, Goodkin DE, Jacobs LD, et al.
    Impact of interferon beta 1a on neurologic disability in relapsing remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Neurology 1997;49:358-363.
    Abstract

  • Vartanian T.
    An examination of the results of the EVIDENCE, INCOMIN and phase III studies of interferon beta products in the treatment of multiple sclerosis.
    Clin Ther 2003;25(1):105-118.
    Abstract

  • Yong VW.
    Differential mechanisms of action of interferon beta and glatiramer acetate in MS .
    Neurology 2002;56(6):802-808.
    Abstract

Neutralising antibodies

  • Hartung HP, Polman C, Bertolotto A, et al.
    Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report.
    J Neurol 2007.
    Abstract

  • Rice G, Sölberg Sørensen P, Vartanian T.
    Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    J Neurol 2004;251(Suppl 2):25-30.
    Abstract